Mesenchymal stromal cells

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

COVID-19Brain InjurySystemic SclerosisAllogeneic Hematopoietic Stem Cell TransplantationCrohn DiseaseCorneal Ulcer

309 competitors in COVID-19

#DrugCompanyPhaseTrials

1

Mesenchymal stromal cells

Mario Negri Institute for Pharmacological Research

Phase 3

42

Aimovig

Amgen

Preclinical

13

Aldactone

Pfizer

Preclinical

14

Nexavar

Bayer

Preclinical

15

Stivarga

Bayer

Preclinical

16

Activella

Eli Lilly

Preclinical

—7

Calciferol

Jazz Pharmaceuticals

Preclinical

—8

Angiomax

BBaxter Healthcare Corporation

Preclinical

29

Tricor

JJagotec

Preclinical

110

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

COVID-194 trials

Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection

Recruiting·UUniversity of Liege·Phase 1/2·NCT04445454·20 enrolled

Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS

Completed·CCristina Avendaño Solá·Phase 2·NCT04615429·20 enrolled

Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 1·NCT04467047·10 enrolled

Show 1 more trial

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT04466098·8 enrolled

Acute Respiratory Distress Syndrome2 trials

Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells

Unknown status·KKarolinska University Hospital·Phase 1·NCT02215811·10 enrolled

Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome

Completed·OOttawa Hospital Research Institute·Phase 1/2·NCT04400032·15 enrolled

Chronic Graft Versus Host Disease2 trials

Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells

Unknown status·GGuangdong Provincial People's Hospital·Phase 3·NCT02291770·130 enrolled

Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease

Terminated·KKarolinska Institutet·Phase 1·NCT01522716·11 enrolled

Kidney Transplant2 trials

Mesenchymal Stromal Cells in Kidney Transplant Recipients

Terminated·Mario Negri Institute for Pharmacological Research·Phase 1·NCT02012153·3 enrolled

MSC and Kidney Transplant Tolerance (Phase A)

Unknown status·MMonia Lorini·Phase 1·NCT02565459·22 enrolled

Renal Transplant Recipients1 trial

Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients

Completed·LLeiden University Medical Center·Phase 1·NCT02387151·10 enrolled

15 more indications

Liver Transplant1 trial

MSC Therapy in Liver Transplantation

Unknown status·MMonia Lorini·Phase 1·NCT02260375·20 enrolled

Cell Therapy1 trial

Mesenchymal Stromal Cell Therapy in Renal Recipients

Unknown status·LLeiden University Medical Center·Phase 2·NCT02057965·70 enrolled

Crohn Disease1 trial

MSC Intratissular Injection in Crohn Disease Patients

Recruiting·UUniversity of Liege·Phase 1/2·NCT03901235·60 enrolled

Diabetic Foot1 trial

Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells to Non-healing Diabetic Foot Wounds

Terminated·SSteno Diabetes Center Copenhagen·Phase 1·NCT03509870·2 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

Not yet recruiting·SShiCang Yu·Phase 4·NCT06171906·68 enrolled

Acute Graft Versus Host Disease1 trial

MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis

Unknown status·NNational Research Center for Hematology, Russia·Phase 2/3·NCT02270307·40 enrolled

Complication1 trial

Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease

Withdrawn·KKarolinska Institutet·Phase 1/2·NCT02055625

Recessive Dystrophic Epidermolysis Bullosa1 trial

Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa

Unknown status·KKing's College London·Phase 1/2·NCT02323789·10 enrolled

Osteogenesis Imperfecta1 trial

Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta

Completed·NNationwide Children's Hospital·Phase 1·NCT01061099·5 enrolled

Brain Injury1 trial

Effects of Intravascular Administration of Mesenchymal Stromal Cells Derived from Wharton's Jelly of the Umbilical Cord on Systemic Immunomodulation and Neuroinflammation After Traumatic Brain Injury.

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06146062·68 enrolled

Kidney Disease1 trial

NEPHSTROM for Diabetic Kidney Disease

Terminated·Mario Negri Institute for Pharmacological Research·Phase 1/2·NCT02585622·29 enrolled

Systemic Sclerosis1 trial

Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis

Recruiting·UUMC Utrecht·Phase 1/2·NCT03211793·20 enrolled

Conditioning1 trial

Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs

Completed·SStanford University·Phase 2·NCT00957931·6 enrolled

Corneal Ulcer1 trial

Efficacy of Locally Delivered Allogeneic Mesenchymal Stem Cells for Promoting Corneal Repair

Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT05705024·38 enrolled

SARS-CoV21 trial

Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of COVID-19 Induced ARDS: A Non-Blinded Randomized, Controlled Study

Completed·BBaylor College of Medicine·Preclinical·NCT04345601·28 enrolled

Details

Drug Info

Related News